The efficacy of UPA can be attributed to aberrant JAK-STAT pathway signaling as a contributor of cutaneous LP and LPP pathogenesis, including the JAK1 pathway.2 The gene discussed is SOAT1; the disease is urokinase-type plasminogen activator measurement.